Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2025-11-14 00:00:00 ET · period of report 2025-11-12 · accession 0001470831-25-000317 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-14 | 2025-11-12 | BBIO | Valantine Hannah | Dir | S - Sale+OE | $66.07 | -25.5K | 7,465 | -77% | -$1.68M |
| D | 2025-11-14 | 2025-11-12 | BBIO | Valantine Hannah | Dir | M - OptEx | $48.45 | +25.5K | 32.9K | +341% | +$1.23M |
| D | 2025-11-14 | 2025-11-12 | BBIO | Valantine Hannah | Dir | M - OptEx | $0.00 | -25.5K | 25.5K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-12 | S | D | 25,484 | $66.07 | 7,465 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-12 | M | A | 25,484 | $48.45 | 32,949 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-11-12 | M | D | 25,484 | $0.00 | 25,484 | D | $48.45 · — to 2031-10-24 | 25,484 Common Stock | (F1) The stock option vested and became exercisable in three annual installments after October 25, 2021. |